The revenue beat and raised guidance support the top-line growth narrative, but the widening GAAP loss and EPS miss introduce downside risk. Monitor the next quarter for operating expense control and cash burn trajectory; the stock may trade on the revenue momentum in the near term but could face pressure if losses continue to accelerate.
Price Chart
Executive Summary
Kestra Medical reported F1Q27 (July 31, 2026) revenue of $31.0M, up 60% YoY and beating the $29.0M consensus estimate by 6.9%. However, GAAP EPS of -$0.75 missed the Street consensus of -$0.63 by 19%, and the GAAP net loss widened to -$44.1M from -$25.8M a year ago. The company raised FY27 revenue guidance to $141M (from $137M), signaling continued strong top-line momentum, but the deepening operating losses and EPS miss temper the bullish narrative, making this a mixed report with notable revenue upside offset by deteriorating bottom-line performance.
Key Financial Metrics
Key Facts
- Revenue of $31.0M beat the $29.0M consensus estimate by 6.9% and grew 60% YoY.
- GAAP EPS of -$0.75 missed the Street consensus of -$0.63 by 19% (GAAP net loss widened to -$44.1M from -$25.8M).
- Gross margin expanded to 56.5% from 45.7% a year ago, driven by volume leverage and in-network mix.
- FY27 revenue guidance raised to $141M (from $137M), representing 48% YoY growth.
- Adjusted EBITDA loss widened to -$24.0M from -$19.4M; GAAP operating expenses rose to $55.2M from $37.7M.
- Cash, cash equivalents, and investments totaled $244.7M; total liquidity of ~$320M including undrawn term loan.
Financial Impact
Revenue beat consensus by ~$2.0M (6.9%), but EPS missed by -$0.12 (19% miss). FY27 guidance raised by $4M.
Risk Factors
- GAAP net loss widening faster than revenue growth, with operating expenses up 46% YoY.
- EPS miss of 19% vs consensus may trigger negative sentiment among bottom-line-focused investors.
- Cash burn remains high: operating cash flow of -$32.3M in the quarter, though liquidity of $320M provides runway.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3361529 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Insider Cluster | $28.76 | awaiting T+20 | — | $29.42 (+2.29%) |
Oct 20, 2026 6d ago | 144 | $27.31 | awaiting T+20 | — | $29.42 (+7.73%) |
Oct 20, 2026 6d ago | ANALYST-UPGRADE | $28.28 | awaiting T+20 | — | $29.42 (+4.03%) |
Sep 30, 2026 26d ago | 144 | $27.12 | awaiting T+20 | — | $29.42 (+8.50%) |
Sep 14, 2026 6w ago | Press Release | $25.18 $26.97 | ▲ +7.11% | ▲ +4.39% | $29.42 (+16.84%) |
Sep 10, 2026 6w ago | Insider Cluster | $22.85 $26.98 | ▲ +18.07% | ▲ +16.21% | $29.42 (+28.75%) |
Sep 10, 2026 6w ago | Press Release | $23.57 $25.77 | ▲ +9.33% | ▲ +7.21% | $29.42 (+24.82%) |
Aug 31, 2026 8w ago | Press Release | $25.12 $28.29 | ▲ +12.62% | ▲ +12.30% | $29.42 (+17.12%) |
Aug 26, 2026 8w ago | Press Release | $26.57 $25.76 | ▼ −3.05% | ▼ −3.27% | $29.42 (+10.73%) |
Aug 11, 2026 10w ago | Insider Cluster | $28.00 $23.57 | ▲ +15.82% | ▲ +13.92% | $29.42 (−5.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers